Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer.

Background: Triple‐negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II‐III TNBC. This study evaluates the impact of NAIC on surgical outcomes versus neoadjuvant chemoth...

Full description

Bibliographic Details

Published in:	Breast Journal Vol. 2026; pp. 1 - 10
Main Authors:	Khadrouche, Tamasine, Morisseau, Mathilde, Selmes, Gabrielle, Vaysse, Charlotte, Franchet, Camille, Massabeau, Carole, Ung, Mony, Maio, Eleonora De, Lacaze, Jean-Louis, Jouve, Eva, Wani, Imtiaz
Format:	research tables/charts Journal Article
Published:	Wiley-Blackwell 7/17/2026
Online Access:	View this record in EBSCOhost